Quantifying HLA-specific antibodies in patients undergoing desensitization

Andrea Zachary, Nancy L. Reinsmoen

Research output: Contribution to journalReview articlepeer-review

Abstract

PURPOSE OF REVIEW: Two major desensitization protocols have been used to eliminate or reduce HLA antibodies to a level that allows transplantation with a low risk of antibody-mediated rejection (AMR). This review will focus on the antibody testing methods used to assess changes in the breadth and strength of antibody levels and the relative strength of donor HLA-specific antibodies (DHSAs). RECENT FINDINGS: Correlations of solid-phase immunoassay (SPI) class I and II levels with the donor-specific T and B cross-match results have shown the acceptable levels of DHSA that correlate with a low risk for AMR. The DSHA levels determined by SPI correlate with cross-match results and with clinical outcome. Therefore, the results of either assay can be used to determine the risk of AMR and when treatment has reduced DSHA to a level safe for transplantation. Monitoring DSHA is important for guiding the number of treatments as well as the timing of additional treatments needed to achieve these acceptable levels. SUMMARY: DSHA monitoring, in both protocols, uses the correlation of solid-phase antibody testing and the donor-specific cross-match to determine the efficacy of the protocol and when the acceptable level of DSHA is achieved permitting transplantation with minimal likelihood of AMR.

Original languageEnglish (US)
Pages (from-to)410-415
Number of pages6
JournalCurrent opinion in organ transplantation
Volume16
Issue number4
DOIs
StatePublished - Aug 1 2011

Keywords

  • IVIg
  • crossmatch
  • desensitization
  • donor HLA-specific antibody
  • solid-phase immunoassays

ASJC Scopus subject areas

  • Immunology and Allergy
  • Transplantation

Fingerprint

Dive into the research topics of 'Quantifying HLA-specific antibodies in patients undergoing desensitization'. Together they form a unique fingerprint.

Cite this